ZURICH (Reuters) - Swiss drugmaker Novartis AG (VX:NOVN) said on Wednesday three members of its executive committee would leave the company following the completion of transactions with GlaxoSmithKline (GSK) (L:GSK) and Eli Lilly (N:LLY) expected in the first half of 2015.
EU antitrust regulators approved U.S. drugmaker Lilly's $5.4 billion (3.36 billion pounds) takeover of Novartis's animal health business last week. Novartis separately agreed in April to buy GSK's oncology products for $14.5 billion and sell its vaccine business to the British drugmaker for $7.1 billion.
George Gunn, division head of Novartis Animal Health, will leave the executive committee once the deal with Lilly is concluded, Novartis said in a statement.
Andrin Oswald, division head of Novartis Vaccines, will leave the company following the completion of the deal with GSK, while Brian McNamara, division head of Novartis OTC (Over-the-Counter), will move to GSK.
(Reporting by Joshua Franklin; Editing by Stephen Coates)